



---

**For Immediate Release**

**Contacts:** Nicole Cottrill  
615.327.7999  
[ncottrill@seig-pr.com](mailto:ncottrill@seig-pr.com)

Shelley Jourard  
905.812.6614  
[sjourard@patheon.com](mailto:sjourard@patheon.com)

**Date:** June 19, 2007

## **Senopsys and Patheon Collaborate to Develop Palatable Drug Products**

**Saugus, Mass.** – Senopsys LLC, a specialty pharmaceutical services company, announced today that it has signed a collaboration agreement with Patheon Inc. (TSX:PTI), a leading global provider of drug development and manufacturing services, to accelerate the development of palatable drug products. Through this collaboration, Senopsys clients will have access to prototype drug formulations manufactured by Patheon and Patheon will be able to offer its clients taste assessment and optimization services.

“The combination of Senopsys’ significant expertise in taste assessment and optimization with our broad development capabilities will provide an excellent platform for supporting our clients with additional solutions for their drug products requiring taste masking,” said Dr. Shabbir Anik, Patheon’s President of Global Pharmaceutical Development Services. “We have a number of clients who are interested in developing palatable dosage forms to support pediatric regulatory requirements for investigational new drugs and life cycle management initiatives for approved drugs. We look forward to working with Senopsys to develop palatable products that meet the needs of diverse patient populations.”

A drug product’s aesthetics – aroma, flavor, texture, mouthfeel – can have a dramatic effect on patient compliance, health outcomes and product sales. Senopsys uses proprietary sensory assessment and formulation tools to develop palatable drug products. The company quantifies the taste masking challenge of drug substances, measures the palatability of prototypes and optimizes the sensory characteristics of drug products to meet the needs of diverse patient populations. Patheon offers a full range of formulation and analytical development, and clinical supplies manufacturing and process optimization capabilities. The company can quickly and cost-effectively manufacture small-scale batches of prototype drug formulations under Good Manufacturing Practices (GMP) guidelines.

“This collaboration with Patheon enhances Senopsys’ ability to conduct taste assessment and optimization studies that require the use of GMP materials,” said Jeff Worthington, Founder and President of Senopsys. “With Patheon’s development and manufacturing capabilities and Senopsys’ taste optimization expertise, our companies will be able to provide our clients with

expanded options for accelerating the clinical and commercial development of their drug products.”

### **About Patheon**

Patheon operates a network of 14 facilities in the United States, Canada and Europe, employing more than 5,200 people and serving a client base of 250 pharmaceutical and biotechnology companies. Through its well-recognized Pharmaceutical Development Services group, Patheon is able to assist its clients in bringing their drug candidates from preclinical stages through to clinical trials, the NDA approval process and, if approved, commercial manufacturing. For further information about Patheon, please visit [www.patheon.com](http://www.patheon.com) or contact the company at [info@patheon.com](mailto:info@patheon.com) or 1-888-PATHEON (Canada and the U.S.).

### **About Senopsys**

Senopsys is a specialty services company dedicated to the development of palatable pharmaceuticals. The company partners with pharmaceutical, biotechnology and drug delivery companies to develop patient acceptable drug products that improve patient compliance, health outcomes and drug sales. Senopsys' FlavorMetrics Taste Assessment Tools are used to quantify the taste masking challenge of drug substances and measure the palatability of drug prototypes and competing products. Using its FlavorOpt Sensory Optimization System, Senopsys applies its knowledge of flavor construction and excipient functionality to develop palatable formulations. For further information about Senopsys, please visit [www.senopsys.com](http://www.senopsys.com) or contact the company at [info@senopsys.com](mailto:info@senopsys.com) or 781-231-1818.

###